We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inhibitor of apoptosis proteins in hematological malignancies.
- Authors
Fulda, S.
- Abstract
Apoptosis or programmed cell death is a key mechanism to control tissue homeostasis, for example, in the hematopoietic system. Thus, resistance to apoptosis can contribute to the development of leukemia or lymphoma. Inhibitors of apoptosis (IAP) proteins block cell death pathways at a central node by interfering with the activation of effector caspases. As increased expression levels of IAPs are found in hematological malignancies and have been correlated with poor prognosis, IAPs could be exploited as therapeutic targets and prognostic markers. Various strategies have been developed to target IAPs for therapeutic purposes in leukemia and lymphoma cells, including small-molecule inhibitors and antisense oligonucleotides. These agents could directly induce apoptosis in malignant cells or sensitize these cells to other cytotoxic agents. Thus, IAPs present promising targets for the development of new biomarkers and cancer therapeutics in hematological malignancies.Leukemia (2009) 23, 467–476; doi:10.1038/leu.2008.329; published online 27 November 2008
- Subjects
APOPTOSIS; CELL death; HOMEOSTASIS; HEMATOPOIETIC system; LEUKEMIA; LYMPHOMAS; OLIGONUCLEOTIDES; BIOMARKERS
- Publication
Leukemia (08876924), 2009, Vol 23, Issue 3, p467
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2008.329